Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1689-1695

  Soga, Yoshimitsu ^a   Yokoi, Hiroyoshi ^a   Urakawa, Tomoko ^a   Tosaka, Atsushi ^a   Iwabuchi, Masashi ^a   Nobuyoshi, Masakiyo ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Follow up; Peripheral artery disease; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ADULT; AGE DISTRIBUTION; AGED; ARTERY DISEASE; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOVASCULAR SURGERY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INTERMITTENT CLAUDICATION; KNEE DISEASE; LEG AMPUTATION; LEG REVASCULARIZATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RESTENOSIS; SEX RATIO; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; CORONARY ARTERY DISEASE; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; HUMANS; INTERMITTENT CLAUDICATION; MIDDLE AGED; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR DISEASES; VASCULAR PATENCY;

EID: 77955084599     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0077     Document Type: Article

References (20)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45(Suppl 1): S5-S67.
2. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/ Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. J Am Coll Cardiol 2006; 47: 1239-1312.
3. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology 1989; 170: 921-940.
4. Murphy TP, Ariaratnam NS, Carney WI Jr, Marcaccio EJ, Slaiby JM, Soares GM, et al. Aortoiliac insuffciency: Long-term experience with stent placement for treatment. Radiology 2004; 231: 243-249.
5. Ferreira M, Lanziotti L, Monteiro M, Abuhadba G, Capotorto LF, Nolte L, et al. Superfcial femoral artery recanalization with self-expanding nitinol stents: Long-term follow-up results. Eur J Vasc Endovasc Surg 2007; 34: 702-708.
6. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained beneft at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115: 2745-2749.
7. Flørenes T, Bay D, Sandbaek G, Saetre T, Jørgensen JJ, Slagsvold CE, et al. Subintimal angioplasty in the treatment of patients with intermittent claudication: Long term results. Eur J Vasc Endovasc Surg 2004; 28: 645-650.
8. Fiotti N, Altamura N, Cappelli C, Schillan M, Guarnieri G, Giansante C. Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents. Eur J Vasc Endovasc Surg 2003; 26: 374-380.
9. Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, et al. Effcacy of cilostazol after endovascular therapy for femo-ropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009; 53: 48-53.
10. Ranke C, Creutzig A, Alexander K. Duplex scanning of peripheral arteries: Correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 1992; 18: 433-440.
11. Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease: Dutch Iliac Stent Trial Study Group. Lancet 1998; 351: 1153-1159.
12. Klein WM, van der Graaf Y, Seegers J, Spithoven JH, Buskens E, van Baal JG, et al. Dutch iliac stent trial: Long-term results in patients randomized for primary or selective stent placement. Radiology 2006; 238: 734-744.
13. Koizumi A, Kumakura H, Kanai H, Araki Y, Kasama S, Sumino H, et al. Ten-year patency and factors causing restenosis after endovas-cular treatment of iliac artery lesions. Circ J 2009; 73: 860-866.
14. Kudo T, Chandra FA, Ahn SS. Long-term outcomes and predictors of iliac angioplasty with selective stenting. J Vasc Surg 2005; 42: 466-475.
15. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, et al. PTA versus Palmaz stent placement in femoropopli-teal artery obstructions: A multicenter prospective randomized study. J Vasc Interv Radiol 2001; 12: 23-31.
16. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Dohi T, et al. Long-term results of endovascular therapy with nitinol stent implantation for TASC II A/B femoro-popliteal artery lesions. Circ J 2009; 73: 2143-2147.
17. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
18. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, et al; REACH Registry Investigators. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-1206.
19. The Long-term Interventions with Pravastatin in Ischemic Disease (LIPID) Study Investigators. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
20. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.